ClinicalTrials.Veeva

Menu

PACAP27 Headache Properties in Migraine Without Aura Patients

D

Danish Headache Center

Status

Completed

Conditions

Migraine Without Aura

Treatments

Drug: Saline
Drug: PACAP27

Study type

Interventional

Funder types

Other

Identifiers

NCT03471039
H-17016232

Details and patient eligibility

About

Pituitary adenylate cyclase-activating polypeptide (PACAP) is a signaling molecule, localized in sensory and parasympathetic perivascular nerves fibres. PACAP exists i to functional iso-forms Pituitary adenylate cyclase-activating polypeptide-38 (PACAP38) and PACAP27.

Enrollment

20 patients

Sex

All

Ages

18 to 60 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Migraine patients meeting International Headache Society (IHS) criteria for migraine without aura of both sexes, 18-60 year, 50-100 kg.

    • Fertile women should use safe contraception. Fertile women do not include hysterectomized women or women who are postmenopausal for at least 2 years. Safe contraception includes either Intra Uterine Device (IUD), birth control pills, surgical sterilization of the woman or depot progestogen.

Exclusion criteria

  • Tension Type headache for more than 5 days the month on average in the last year.

    • All other primary headaches .
    • Headache later than 48 hours before trial start.
    • Daily intake of any medicine other than oral contraception.
    • Ingestion of any form of medicinal product later than 4 times the plasma half-life substance (on trial day), except for oral contraception.
    • Pregnant or breastfeeding women.
    • Headache on the test day or later than 48 hours prior to administration of trial medicine / placebo
    • Migraine within 5 days before the trial date.
    • Ancestral information or clinical signs of (on the day of inclusion):
  • Hypertension (systolic blood pressure> 150 mmHg and / or diastolic blood pressure> 100 mmHg)

  • Hypotension (systolic blood pressure <90 mm Hg and / or diastolic blood pressure <50 mmHg)

    • Cardiovascular disease of all kinds, including cerebrovascular disease.
    • Anamnestic or clinical signs of mental illness or abuse.
    • Patients with glaucoma or prostatic hyperplasia
    • Anamnestic or clinical signs of diseases of any kind such as the investigating physician is considered relevant for participation in the trial.

Trial design

Primary purpose

Health Services Research

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Double Blind

20 participants in 2 patient groups, including a placebo group

Active
Active Comparator group
Description:
PACAP-27
Treatment:
Drug: PACAP27
Placebo
Placebo Comparator group
Description:
Saline
Treatment:
Drug: Saline

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems